Matsuyama, Ryo http://orcid.org/0000-0003-1483-4746
Omata, Tomoyo
Kageyama, Michiharu
Nakajima, Ryota
Kanou, Masanobu
Yamana, Kei
Article History
Received: 14 September 2022
Revised: 31 October 2022
Accepted: 28 November 2022
First Online: 11 December 2022
Declarations
:
: Animal experiments were conducted in accordance with the guidelines for animal experimentation set by the Animal Ethics Committee of the Teijin Institute for Bio-Medical Research, Teijin Pharma Limited, Tokyo, Japan (approval number: A21-031-R). All procedures for human blood collection were conducted in accordance with the guidelines for life science/medical research targeting humans by the Human Ethics Committee of the Teijin Institute for Bio-Medical Research (approval number: HB21-002-M1).
: Written informed consent was obtained from each volunteer.
: R. Matsuyama is an employee of Teijin Pharma Limited and Teijin Limited. T. Omata and M. Kageyama are employees of Teijin Pharma Limited. R. Nakajima, M. Kanou, and K. Yamana are employees of Teijin Limited and are also the board of directors of NOMON Co., Ltd., which is a subsidiary of Teijin Limited. R. Matsuyama and T. Omata have applied for a patent to protect the method of NAD<sup>+</sup> measurement presented in the manuscript.